Vertex Archives -

In the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager

Vertex’s Nicola Massey: the pharmaphorum podcast

https://pharmaphorum.com/sales-marketing/vertex-senior-country-manager-nicola-massey/

News/ News/ R&D

Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal

Richard Staines CRISPR, CRISPR Therapeutics, Editas, gene editing, Vertex 0 Comment

CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to

Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal

https://pharmaphorum.com/news/nobel-winner-charpentiers-crispr-therapeutics-gets-900m-in-reworked-vertex-deal/

News/ News/ News/ R&D/ Sales and Marketing

After Celgene deal, BMS shoots up pharma market cap rankings

Phil Taylor AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, CSL, Daiichi Sankyo, Eli Lilly, Gilead Sciences, GlaxoSmithKline, GlobalData, Johnson & Johnson, M&A, Merck & Co, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda, Vertex 0 Comment

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies

After Celgene deal, BMS shoots up pharma market cap rankings

https://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/

Digital/ News/ News/ Top stories

COVID-19 could cause surge in virtual trials, says Vertex expert

Richard Staines coronavirus, COVID-19, digital, R&D, Vertex, virtual trials 0 Comment

The COVID-19 crisis is causing a surge in interest in ‘virtual trials’ where the bulk of the data

COVID-19 could cause surge in virtual trials, says Vertex expert

https://pharmaphorum.com/news/covid-19-could-cause-surge-in-virtual-trials-says-vertex-expert/

Market Access/ News/ News/ Top stories

Shares in Vertex jump on overnight success of CF triple therapy

Richard Staines COVID-19, cystic fibrosis, market access, pricing, Trikafta, Vertex 0 Comment

Shares in US pharma Vertex were up sharply in premarket trading after its newly-launched cystic fibrosis triple therapy attained blockbuster status

Shares in Vertex jump on overnight success of CF triple therapy

https://pharmaphorum.com/news/shares-in-vertex-jump-on-overnight-success-of-cf-triple-therapy/

Market Access/ Views & Analysis/ Views and analysis

The 4 biggest pharma market access stories of 2019

George Underwood biosimilars, cystic fibrosis, fda, HTA, NICE, pricing, Vertex 0 Comment

What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive

The 4 biggest pharma market access stories of 2019

https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/

Market Access/ News/ News/ Top stories

After four-year wait, patients in England finally get Vertex’s cystic fibrosis drugs

Richard Staines cystic fibrosis, market access, Vertex 0 Comment

NHS England has signed an agreement with US pharma Vertex covering all the company’s licensed cystic fibrosis medicines,

After four-year wait, patients in England finally get Vertex’s cystic fibrosis drugs

https://pharmaphorum.com/news/breaking-news-nhs-signs-agreement-with-vertex-covering-all-cystic-fibrosis-drugs/

News/ News/ R&D/ Top stories

Vertex looks beyond cystic fibrosis with $950m Semma buy

Phil Taylor M&A, metabolic diseases, stem cell therapy, type 1 diabetes, Vertex 0 Comment

Vertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including

Vertex looks beyond cystic fibrosis with $950m Semma buy

https://pharmaphorum.com/news/vertex-looks-beyond-cystic-fibrosis-with-950m-semma-buy/

Market Access/ News/ News

Scotland’s cost regulator rejects Vertex cystic fibrosis drugs

Richard Staines cost-effectiveness, cystic fibrosis, market access, Rare diseases, Vertex 0 Comment

Scotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of

Scotland’s cost regulator rejects Vertex cystic fibrosis drugs

https://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/

Trending

Vertex

Login